Articles

About three-quarters of last year’s job gains were in three industries. That’s affecting workers’ perceptions of the job market and sparking worries of a sharp slowdown ahead.

President Joe Biden used his State of the Union address on Thursday night to reveal his administration’s plan to ease housing costs in the U.S. These are the early winners, and potential losers, according to experts.

Property owners say time is running out as the real-estate industry’s finances grow more dire, and claim the federal government needs to remove funding obstacles preventing conversion projects from coming to fruition.

Recent transactions by both Amazon’s chief executive and a board member seem linked to the stock’s price, says an expert.

The FDA on Friday said it approved Novo Nordisk’s popular weight-loss drug Wegovy to reduce the risk of severe heart issues in overweight or obese adults.

Some crypto bulls are now eyeing $100,000 as bitcoin’s next level, after the leading cryptocurrency on Friday briefly topped $70,000 for the first time in its history.

Market gurus love to complain about the fact that the performance of indexes like the S&P 500 is increasingly being driven by a small cadre of megacap stocks.

It may be surprising to see safe-haven gold score record highs at generally the same time as riskier assets such as bitcoin, U.S. stock indexes, and other global stock benchmarks. Here’s what’s going on.

SoFi’s bid to raise capital sparked a record one-day selloff in its shares earlier this week. One analyst thinks Wall Street may have misunderstood the impact of that financial move.

The social-media platform could find itself at odds with its loyal user base as it strives for profitability, said Jon Keidan, founder and managing partner of venture fund Torch Capital.

Viking Therapeutics Inc.’s stock fell 5.6% Friday, in a pullback from recent highs, after strong data from Novo Nordisk on an oral version of its weight-loss drug raised the competitive bar for Viking, which is expected to release data from its oral-drug trial late this quarter.

‘It’s not fair,’ the president said during the State of the Union address